Une candidature complète en une minute
Un CV et une lettre de motivation personnalisés, prêts à envoyer.
Recipharm is seeking a scientific leader to guide RNA process development across IVT and downstream operations, enabling scale-up, tech transfer, and GMP manufacturing support. The role focuses on designing, executing, and interpreting critical experiments for RNA modalities such as mRNA, saRNA, siRNA, and circRNA.
As a leader in the RNA process science group, you will mentor scientists, drive cross-functional collaborations with analytics, tech transfer, and manufacturing, and contribute to
This position reports to the Head of Technical Operations and plays a key role in leading laboratory /experimental approaches for optimized RNA production. They will lead the efforts to design, execute, and interpret critical experiments for the success of various RNA modalities in activities including IVT high throughput screening, downstream development, process scale-up and tech transfer. This role will also support downstream process development for plasmid purification and related analytical development for in-process monitor and final product release. The individual will work collaboratively in a cross‑functional environment including analytics, tech transfer, GMP manufacturing and Quality. The successful candidate has a big potential to grow as a leader in nucleic acid process science group.
The physical demands described here are representative of those that must be met by an employee to successfully perform the essential functions of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.
Annual Base Salary Range from $145,000 to $155,000
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,500 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including, sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and, pharmaceutical product development. Its biologics segment, ReciBioPharm, works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre‑clinical to clinical and commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live‑microbial biopharmaceutical products, nucleic acid‑based mRNA and plasmid DNA production. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com and www.recibiopharm.com